2022.02.03
2021.07.09
FierceBiotech: I-Mab boards popular mRNA train with 2 biotech collaborations
Read at FierceBiotech2021.05.19
2021.5-Endpoints: #ASCO21: AbbVie-partnered Chinese biotech with first-in-class ambitions showcases early data on CD73 antibody
Read at Endpoints2021.05.19
2021.5-FierceBiotech: ASCO: I-Mab’s checkpoint inhibitor drug helper uliledlimab sees early promise in Tecentriq cancer combo test
Read at FierceBiotech2021.04.27
2021.4-Biocentury: I-Mab is pursuing mRNA therapies, eyeing orally delivered antibodies for ‘third wave’ of its immuno-oncology pipeline
Read at Biocentury2021.04.15
2021.4-Biocentury: Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making
Read at Biocentury2021.03.11
2021.3-Biocentury: I-Mab signs first two deals of immuno-oncology discovery initiative
Read at Biocentury2021.01.04
Endpoints: I-Mab —A Biotech on the Rise with Inspired Science
Read at Endpoints2020.09.13
Nature BioPharma Dealmakers, September 2019: I-Mab Biopharma company profile
Read at Nature BioPharma Dealmakers2020.09.05